Daiichi Sankyo to restructure its commercial organization, appointing Ken Keller as chief commercialization officer
read at Endpoints ↗Neutral
Daiichi Sankyo announced plans to overhaul its commercial operations, with a split of its commercialization activities slated for April 1, 2027.
The company has appointed veteran executive Ken Keller as chief commercialization officer to lead the redesign and implement new market strategies.
Separately, Novo Nordisk's GPCR partnership has named Alex Hoffman as its new chief medical officer to support ongoing research initiatives.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Daiichi Sankyo to give commercial team a makeover; Novo Nordisk's GPCR partner finds CMO”
read at Endpoints ↗93 words · retrieved Aug 28
comments(0)
5-min edit window · permanent after that